Browse News
Filter News
Found 149 articles
-
AIVITA Biomedical Strengthens Board of Directors with Appointment of Ex-Biogen CEO Michel Vounatsos
2/27/2024
AIVITA Biomedical, Inc. today announced the appointment of distinguished healthcare executive Michel Vounatsos to its board of directors.
-
Gene Editing Market Size Expected to Reach USD 29.93 Bn by 2032
12/22/2023
The global gene editing market size is estimated to reach around USD 29.93 billion by 2032, increasing from USD 6.94 billion in 2022.
-
Partners Biogen and Sage Therapeutics had sought approval for the therapy in both postpartum depression and major depressive disorder, but the FDA rejected the application for the latter.
-
Biogen, and partner Denali, are discontinuing the Phase III LIGHTHOUSE study of BIIB122 in Parkinson’s disease due to the trial’s long timeline and complexity.
-
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
5/18/2023
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results.
-
During its Q1 earnings call Tuesday, Biogen announced a handful of program pauses and cuts and touted the potential of anticipated approvals.
-
Legend Biotech Establishes Strategic Advisory Board
4/3/2023
Legend Biotech Corporation announced the formation of a strategic advisory board and the appointments of Michel Vounatsos, former CEO of Biogen Inc., and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors.
-
GSK and Sanofi veteran Christopher A. Viehbacher will take over as chief executive officer for Biogen. He replaces Michel Vounatsos, whose departure was announced in May.
-
Biogen Names Christopher Viehbacher President and Chief Executive Officer
11/10/2022
Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14.
-
Biogen may have found its CEO in Mathai Mammen - former head of research and development in pharmaceuticals at Johnson & Johnson.
-
Eisai, Biogen Revive Anti-Amyloid Alzheimer's Theory with Positive Phase III Data (Updated)
9/28/2022
The anti-amyloid approach to treating Alzheimer's disease is seeing new life after Eisai and Biogen announced that lecanemab slowed progression of disease in a Phase III study. -
Lecanemab Confirmatory Phase 3 Clarity Ad Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer's Disease
9/28/2022
Eisai Co., Ltd. and Biogen Inc. announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD with confirmed presence of amyloid pathology in the brain.
-
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of APOE4 Genotype on ARIA-E Incidence at the Alzheimer's Association International Conference (AAIC) 2022
8/4/2022
Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab and the modeling simulation of the impact of ApoE4 genotype on the incidence of amyloid-related imaging abnormalities.
-
At Biogen's quarterly conference call, outgoing CEO Michel Vounatsos emphasized a strong balance sheet and 10 exciting late-stage programs. The company also raised its 2022 guidance.
-
THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
7/5/2022
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (development code: BAN2401).
-
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
5/9/2022
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab.
-
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.
-
Biogen announced the leadership change in its quarterly financial report. Michel Vounatsos plans to depart the company when a new CEO is found.
-
Latest Findings On Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship To Clinical Outcomes And Dosing Regimens - Presented At AD/PD™ 2022 Annual Meeting
3/21/2022
Eisai Co., Ltd. and Biogen Inc. announced that the latest findings on lecanemab, an investigational anti-amyloid-beta protofibril antibody being developed for the treatment of early Alzheimer's disease, were presented at the Aβ Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases March 15-20 in Barcelona, Spain and virtually.
-
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).